Gene Thrive 2026 was founded on the principle that the "proof of concept" era for gene therapy is now behind us. As we navigate the realities of 2026, the industry is no longer just asking if we can edit the human genome, but how we can do so with surgical precision for millions of patients. Our summit serves as the critical bridge between groundbreaking academic research and large-scale industrial execution. We are dedicated to catalyzing the shift from treating rare, ultra-orphan conditions to addressing the world’s most prevalent chronic diseases, including cardiovascular failure, neurodegeneration, and metabolic disorders.

Our mission is to dismantle the bottlenecks that prevent life-altering therapies from reaching the bedside. While discovery remains vital, the current landscape demands a relentless focus on the "Last Mile"—the complex intersection of AI-optimized manufacturing, scalable delivery platforms, and sustainable reimbursement models. Gene Thrive 2026 brings together the architects of the new bio-economy: from the scientists engineering the next generation of non-viral vectors to the industrial leaders building the modular factories of the future. We provide the forum where Chemistry, Manufacturing, and Controls (CMC) excellence meets regulatory harmony to ensure global patient access.